Melissa L. Johnson, MD, spoke about the design of the phase 3 POSEIDON trial how its data led to the recent approval of tremelimumab plus durvalumab and chemotherapy in patients with advanced non–small cell lung cancer.
Approval Alert | Tremelimumab Plus Durvalumab and Chemotherapy in Advanced Non–Small Cell Lung Cancer
The FDA has approved tremelimumab plus durvalumab for patients with metastatic non–small cell lung cancer based on findings from arms 1 and 3 of the phase 3 POSEIDON trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
